BeiGene (BGNE) Update / Briefing June 26, 2025 08:30 AM ET Speaker0 Hello, everyone. Welcome to b one medicine's twenty twenty five investor research and development day. My name is Liza Heaps. I'm senior director of investor relations at b one. We are very excited to host our investor event today, both in person in New York City and online for our global attendees. Thank you all very much for joining us. This is truly an exciting time at b one, and we are thrilled to walk you through recent progress to dat ...

Sanofi to advance Kymera’s next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474 In preclinical testing, KT-485 demonstrated increased selectivity and potency with a favorable safety profile Kymera is eligible for up to $975 million in collaboration milestones, double digit royalties,and may opt-in to 50/50 development and profit share of KT-485 in the U.S. WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KY ...

Key Takeaways Cal-Maine Foods, Inc. (CALM) and Tyson Foods (TSN) are leading U.S. producers in protein-based food products, eggs for CALM and meat (chicken, beef, pork) for TSN. Both operate in the essential food sector with exposure to commodity price swings and consumer staple demand. Ridgeland, MS-based Cal-Maine, with a market capitalization of $4.6 billion, is the nation's largest producer and distributor of fresh shell eggs. Its diverse offerings include conventional, cage-free, organic, brown and rea ...

On Monday, HC Wainwright initiated coverage on Septerna, Inc. SEPN, citing a next-generation drug design platform aimed at hitherto-undruggable targets.Septerna is working on G protein-coupled receptor (GPCR) drug discovery powered by its proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies.It has led to the discovery and development of its deep pipeline of oral small molecule product candidates focused initially on treating patients in three ...

ProMIS Neurosciences (PMN) FY Conference June 17, 2025 07:00 AM ET Speaker0 Hello everyone and welcome to this latest series of fireside chats here at the Perspectives on Neurology mini conference hosted by H. C. Wainwright. My name is Ram Selvaraju and I'm a Managing Director and Senior Healthcare Equity Research Analyst here within Wainwright's Equity Research Department. I'm joined here today by Neil Warmah, Chief Executive Officer of Promise Neurosciences, a publicly traded biotechnology company focusin ...

NORTH CHICAGO, Ill., June 16, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) did not meet the primary endpoint of overall survival (OS) with a hazard ratio (HR) of 0.908; stratified log-rank, p=0.3772. No new safety signals were observed.1 Results from the VERONA trial will be available in a future medical congress and/or publication. Any ...

The biopharmaceuticals industry is both exciting and risky for investors. Many leading growth stocks in the U.S. market are found in this sector, due to the significant rallies that biopharmaceutical companies experience when a key positive trial result is announced or an important drug receives government approval. On the other hand, a host of biopharma firms face near-constant threats of collapse, given that most of these companies lack sufficient revenue to sustain operations for long unless a breakthrou ...

Nurix Therapeutics (NRIX) Update / Briefing June 12, 2025 08:00 AM ET Speaker0 Welcome to the New York's Therapeutics twenty twenty five investor call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session. I would now like to turn the conference over to Newark's President and CEO, Arthur Sands. Arthur, you may begin. Speaker1 Thanks, Paul. Welcome to our call and our presentation today entitled meeting the needs of patients with CLL and Waldenstrom's ...

PRESS RELEASE In addition to patent protection, AB8939 is also eligible for regulatory data protection in Canada, preventing generic competition for a period of 8 years following initial approval. AB8939 has also received orphan drug designation for AML from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). This orphan drug designation provides 10 and 7 years of market exclusivity in Europe and the United States, respectively, after product approval. A separate secondar ...

Novavax (NVAX) FY Conference June 11, 2025 02:00 PM ET Speaker0 Are we ready to go? Are we live? Oh, hello, everyone. Speaker1 Hi, I'm John Jacobs, CEO of Novavax, and I'm joined here today by Jim Kelly, our CFO, and Doctor. Roxandra Draghia, who heads up our R and D. I want to thank everyone who's here today to join us and listening in to our presentation at the Goldman Sachs forty sixth Annual Global Healthcare Conference. Today's 06/11/2025. I'll advance the slide to our cautionary note regarding forward ...